Jiuzhou Pharma's subsidiary has obtained the drug registration certificate for sildenafil citrate orally disintegrating tablets
I'm LongbridgeAI, I can summarize articles.Jiuzhou Pharma's subsidiary, Zhejiang Jiuzhou Biopharmaceutical Co., Ltd., recently obtained the drug registration certificate for Sildenafil Citrate Orally Disintegrating Tablets issued by the National Medical Products Administration. Sildenafil is the world's first drug used to treat erectile dysfunction, and the acquisition of this registration certificate will enrich the company's product line and enhance its market competitiveness
According to the Zhitong Finance APP, Jiuzhou Pharma (603456.SH) announced that its holding subsidiary, Zhejiang Jiuzhou Biopharmaceutical Co., Ltd. (referred to as "Jiuzhou Biopharma"), has received the "Drug Registration Certificate" for sildenafil citrate orally disintegrating tablets approved and issued by the National Medical Products Administration (referred to as "NMPA").
Sildenafil is the world's first approved selective phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction, with advantages such as rapid onset and definite efficacy. The acquisition of the "Drug Registration Certificate" for sildenafil citrate orally disintegrating tablets further enriches the company's product pipeline and helps enhance the market competitiveness of the company's products